SGLT-2 Therapy Center

Dr. Aaron Vinik joins Diabetes in Control publisher Steve Freed at the AACE 2016 convention in Orlando, Florida. In Part 6 of this Exclusive Interview, Steve asks Dr. Vinik his opinion on type 1 and SGLT-2s.

Dr. Aaron Vinik joins Diabetes in Control publisher Steve Freed at the AACE 2016 convention in Orlando, Florida. In Part 5 of this Exclusive Interview, Dr. Vinik explains the caution on the part of doctors to use the latest SGLT-2 medications despite apparent benefits.

New study indicates canagliflozin superior to glimepiride in lowering A1C.

Guest article by David Kliff, Diabetic Investor: Panel further assessing date that SGLT-2 drug shows actual benefit for heart.

Study announces a new benefit in addition to reductions in major adverse cardiovascular events.

With so much breaking news surrounding SGLT-2 Inhibitors at ADA, what conclusions can we draw? Viewpoints from our guest editorialist David Kliff, and DIC advisory board member Dr. George Bakris.

At the 2016 conference in New Orleans, the latest research on SGLT-2 Inhibitors was on display.

The National Institute of Health and Care Excellence (NICE) has recommended that SGLT-2 inhibitors on the UK market can be used earlier in patients with diabetes

Study shows the SGLT-2 inhibitor can lower HbA1c, BP, and weight in T2DM patients.

FDA issues alert about interim safety results from ongoing clinical trial, but study of potential canagliflozin amputation risk is ongoing.